Molecular targets for liver cancer therapy: From screening of target genes to clinical trials

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Cancer develops from accumulating genetic changes, making oncogene inactivation and tumor suppressor gene restoration key treatment strategies.
• Genome-based drug discovery identifies target genes for therapies like monoclonal antibodies, small molecules, and antisense drugs.
• Sorafenib, a multikinase inhibitor, has shown effectiveness in advanced hepatocellular carcinoma (HCC) clinical trials.

Purpose of the Study:

• To review advancements in microarray technology for liver cancer research.
• To discuss innovations and approaches for discovering novel therapeutic targets in HCC.
• To present findings on gene target therapy using monoclonal antibodies and molecular diagnostic markers.

Main Methods:

• Microarray technology for identifying novel therapeutic targets affecting cell growth in HCC.
• Whole-genome epigenetic aberration analysis using promoter arrays.
• ChIP-chip analysis with tiling arrays and high-throughput sequencing for drug discovery.
• Development of molecular diagnostic markers for patient stratification in vivo.

Main Results:

• Microarray technology has enabled the identification of candidate target genes for HCC.
• Various advanced genomic and epigenomic analyses are being applied to drug discovery.
• Gene target therapy with monoclonal antibodies and molecular diagnostics shows promise.

Conclusions:

• Microarray technology is pivotal in advancing liver cancer research and therapeutic target discovery.
• Integrating genomic and diagnostic approaches is essential for effective HCC treatment.
• Further development of targeted therapies and diagnostic markers is needed for improved patient outcomes.